From the Research
Management of nerve damage from COVID-19 should prioritize a multifaceted approach, including medications for pain and inflammation, immunomodulatory therapies, physical therapy, occupational therapy, and respiratory support, as outlined in the most recent study 1. The goal of this approach is to address both the inflammatory processes causing nerve damage and the functional limitations resulting from that damage, with the aim of maximizing recovery of neurological function and improving quality of life. Key components of this approach include:
- Medications such as gabapentin (300-1200 mg three times daily), pregabalin (75-300 mg twice daily), or duloxetine (30-60 mg daily) to address neuropathic pain and inflammation
- Immunomodulatory therapies like intravenous immunoglobulin (IVIG) at 2 g/kg divided over 2-5 days or corticosteroids like prednisone (starting at 40-60 mg daily with gradual tapering) for severe inflammatory neuropathies
- Physical therapy to maintain muscle strength and prevent contractures, typically scheduled 2-3 times weekly for several months
- Occupational therapy to help patients regain independence in daily activities
- Respiratory support ranging from supplemental oxygen to mechanical ventilation for respiratory complications from nerve damage affecting breathing muscles Regular neurological assessments are crucial to monitor recovery progress and adjust treatment plans accordingly, as highlighted in 1 and supported by earlier studies 2, 3, 4, 5.